A Phase 3 interventional study of HH-120 Nasal Spray and Placebo in COVID-19, sponsored by Huahui Health. Completed at 2 sites in China. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Huahui Health · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.
Among the 472 studies in COVID-19 with a site in China, this one is the 60th largest by enrollment of the 330 interventional ones that give a count, is one of 104 that started in 2023, is one of 46 in phase 3, and was the 391st registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China, United States, Argentina and 16 more countries
Ages 12+
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Sichuan Provincial People's Hospital · Sites in China
Ages 18–90
WestVac Biopharma Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
472 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 91 · Phase 3 58 · Phase 4 53
First in 2013; this study’s year is marked. 104 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 918 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 200 across the 330 interventional studies, 388 across the 142 observational. Of the 207 that completed or were terminated, 5 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 472 have an industry lead sponsor. The 10 most frequent:
Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Huahui Health has 5 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07678619Peking UniversitySmart Analysis and Decision-Making for Emerging Infectious Diseases | 2027-07-17 |
Add all 3 to your calendar (.ics) → With an account.
Among the 472 studies in COVID-19 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
During this study, participants will receive HH-120 nasal spray treatment for 7 consecutive days, the efficacy and safety of HH-120 nasal spray will be assessed throughout the study period mainly based on the incidence of symptomatic SARS-CoV-2 infection and adverse events, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HH-120 Nasal Spray
Drug: HH-120 Nasal Spray
Placebo
Drug: Placebo
HH-120 nasal spray 8 times per day for 7 consecutive days
Placebo 8 times per day for 7 consecutive days
The incidence of symptomatic SARS-CoV-2 infection
Incidence of participants with quantitative Real-Time polymerase chain reaction (qRT-PCR) confirmed SARS-CoV-2 infection and COVID-19 related symptom
Time frame: Up to 7 days
The incidence of SARS-CoV-2 infection
Time frame: Up to 7 days
The changes in SARS-CoV-2 viral nucleic acid load
Time frame: Up to 7 days
The change of viral load by qRT-PCR
Time frame: Up to 7 days
Incidence and severity of adverse events
Time frame: Up to 21 days
The incidence of symptomatic SARS-CoV-2 infection
Time frame: Up to 3 days
The incidence of symptomatic SARS-CoV-2 infection
Time frame: Up to 5 days
Time to onset of first COVID-19 related symptom
Time frame: Up to 7 days
Proportion of participants who progress to moderate/severe/critical type of COVID-19 or death
Time frame: Up to 21 days
The incidence of symptomatic SARS-CoV-2 infection in different subgroups
Time frame: Up to 7 days
The incidence and titer of antidrug antibody (ADA)
Time frame: Up to 21 days
Ran from Mar 2023 to primary completion in Mar 2024, 11 months.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2025 → Mar 2024 and completion Apr 2026 → Apr 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HH-120